Anavex Life Sciences Stock
Anavex Life Sciences Corp.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Terrie Kellmeyer
- Employees
- 34
- Market cap
- $121 M
- IPO
- 02/08/2006
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both…
Anavex Life Sciences stock: price history
1D
-11.5%
1W
-12.1%
1M
-44.5%
6M
-64.0%
YTD
-63.2%
1Y
-85.5%
2Y
-76.3%
5Y
-92.5%
10Y
-61.1%
Next earnings date
Next earnings date
24/11/2026 (in 38 days)
Volatility around earnings
~10% stronger price swings than usual
Ask the agents about Anavex Life Sciences
Analyst assessment of Anavex Life Sciences
PRICE TARGET LOW
US$11.00
CONSENSUS
US$11.00
MEDIAN
US$11.00
PRICE TARGET HIGH
US$11.00
0
STRONG BUY
11
BUY
2
HOLD
0
SELL
0
STRONG SELL
13
TOTAL · Buy
As of: 31/03/2026
Anavex Life Sciences stock metrics
P/E
-5.01
P/B
1.07
EV/EBITDA
-0.14
RETURN ON EQUITY
-2.8%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
96.9%
FLOAT SHARES
89,808,408
AVG. DAILY VOLUME (30D)
1,127,323
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Anavex Life Sciences stock
What does Anavex Life Sciences do?
Anavex Life Sciences Corp. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Terrie Kellmeyer, the company employs around 34 people.
The IPO was on 02/08/2006; the stock trades on NASDAQ under the ticker AVXL.
What do analysts say about Anavex Life Sciences stock?
13 analysts rate the stock, the consensus is Buy (as of 31/03/2026).
The average price target is US$11.00, ranging from US$11.00 to US$11.00, with a median of US$11.00.
This is an external assessment, not a statement by Market Jury.
When does Anavex Life Sciences report next?
The next earnings date is 24/11/2026.
Around past earnings, price swings were roughly 10% stronger than usual.
Does Anavex Life Sciences pay a dividend?
No, Anavex Life Sciences currently does not pay a dividend.
Which stocks are comparable to Anavex Life Sciences?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Anavex Life Sciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess Anavex Life Sciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.